tocilizumab
Showing 26 - 50 of 243
COVID-19 Trial in New York (Tocilizumab)
Active, not recruiting
- COVID-19
- Tocilizumab
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 21, 2022
Covid19 Trial in Ipatinga, Varginha, Aracaju (Tocilizumab, Heparin - Therapeutic dosage, Heparin - Prophylactic dosage)
Completed
- Covid19
- Tocilizumab
- +2 more
-
Ipatinga, Minas Gerais, Brazil
- +2 more
Mar 17, 2022
COVID-19 Virus Infection, Cytokine Storm, Corticosteroid Trial (Methylprednisolone, Tocilizumab)
Withdrawn
- COVID-19 Virus Infection
- +3 more
- Methylprednisolone
- Tocilizumab
- (no location specified)
Nov 22, 2021
Acute Myocardial Infarction, Cardiogenic Shock Trial in Copenhagen (Tocilizumab, Dobutamine, NaCl 0.9%)
Recruiting
- Acute Myocardial Infarction
- Cardiogenic Shock
- Tocilizumab
- +2 more
-
Copenhagen, DenmarkRigshospitalet, Copenhagen University Hospital
Apr 21, 2022
Rheumatoid Arthritis Trial in China (Tocilizumab, MTX, Placebo Matched to MTX)
Completed
- Rheumatoid Arthritis
- Tocilizumab
- +3 more
-
Baotou, China
- +19 more
Dec 5, 2022
Rapid Progressive Interstitial Lung Diseases Trial in Beijing (Tocilizumab)
Recruiting
- Rapid Progressive Interstitial Lung Diseases
- Tocilizumab
-
Beijing, ChinaPeking Union Medical College Hospital
Dec 19, 2021
COVID-19 Trial in Worldwide (Tocilizumab)
Recruiting
- COVID-19
- Tocilizumab
-
Orange, California
- +13 more
Aug 4, 2022
ive Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept
Completed
- Rheumatoid Arthritis
- Tocilizumab
- Abatacept
-
Boston, MassachusettsBrigham and Women's Hospital
Nov 15, 2021
Hematologic Malignancy, Bone Marrow Transplant Trial in New York (Tocilizumab, Fludarabine, Melphalan)
Recruiting
- Hematologic Malignancy
- Bone Marrow Transplant
- Tocilizumab
- +4 more
-
New York, New YorkWeill Cornell Medical College
Oct 27, 2021
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Glofitamab
- +4 more
-
Boston, Massachusetts
- +1 more
Sep 12, 2023
Antibody-mediated Rejection Trial in Gothenburg, Stockholm, Uppsala (Tocilizumab)
Recruiting
- Antibody-mediated Rejection
- Tocilizumab
-
Gothenburg, Vastra Gotaland Regioin, Sweden
- +2 more
Feb 16, 2022
Tocilizumab on Procalcitonin and Other Biochemical and Clinical
Not yet recruiting
- COVID-19 Pneumonia
- ARDS
- Tocilizumab
-
Imsida, MaltaMater Dei Hospital
Sep 2, 2021
Schizophrenia, Psychotic Disorders Trial in Augusta (Tocilizumab, Normal saline)
Recruiting
- Schizophrenia
- Psychotic Disorders
- Tocilizumab
- Normal saline
-
Augusta, GeorgiaAugusta University
Jul 27, 2021
Acute Leukemia, Chronic Leukemia, Lymphoma Trial in Milwaukee (Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg))
Terminated
- Acute Leukemia
- +3 more
- Nivolumab (.25 mg/kg)
- +2 more
-
Milwaukee, WisconsinFroedtert Hospital and the Medical College of Wisconsin
Oct 4, 2021
Giant Cell Arteritis Trial in Boston (Tocilizumab, Prednisone)
Recruiting
- Giant Cell Arteritis
- Tocilizumab
- Prednisone
-
Boston, MassachusettsMassachusetts General Hospital
Jul 23, 2021
Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Cevostamab
- +2 more
- (no location specified)
Jun 22, 2023
Systemic Lupus Erythematosus Trial (RO7507062, Tocilizumab)
Not yet recruiting
- Systemic Lupus Erythematosus
- RO7507062
- Tocilizumab
- (no location specified)
Apr 19, 2023
Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory Trial (Glofitamab, Pirtobrutinib, Obinutuzumab)
Not yet recruiting
- Mantle Cell Lymphoma
- Mantle Cell Lymphoma Refractory
- Glofitamab
- +3 more
- (no location specified)
Apr 18, 2023
Schizophrenia Trial in Augusta (Tocilizumab)
Completed
- Schizophrenia
- Tocilizumab
-
Augusta, GeorgiaGeorgia Health Sciences University
Jul 27, 2021
MDD Trial (Tocilizumab, Placebo, Whole-Body Hyperthermia)
Not yet recruiting
- Major Depressive Disorder
- Tocilizumab
- +2 more
- (no location specified)
Aug 23, 2022